Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome
Open Access
- 1 March 2001
- journal article
- review article
- Published by SAGE Publications in Lupus
- Vol. 10 (3) , 241-245
- https://doi.org/10.1191/096120301667789546
Abstract
Antiaggregant and anticoagulant drugs are essential in the management of the manifestations due to antiphospholipid syndrome (APS) in patients with primary Hughes' syndrome or systemic lupus erythematosus. Coumadin derivatives (warfarin and acenocumarol), heparin and aspirin are used for secondary thromboprophylaxis and treatment of recurrent miscarriage. The available evidence for each indication is reviewed in this paper. There is still debate regarding the optimal intensity of oral anticoagulation, the best drug combination for pregnancy failure in APS and the management of asymptomatic patients with antiphospholipid antibodies.Keywords
This publication has 40 references indexed in Scilit:
- Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trialThe Lancet, 2000
- The anti-phospholipid antibody syndrome (Hughes syndrome): therapeutic aspectsBest Practice & Research Clinical Rheumatology, 2000
- Management of Thrombosis in the Antiphospholipid SyndromePublished by Springer Nature ,2000
- Platelet-Active DrugsChest, 1998
- Guidelines on oral anticoagulation: third editionBritish Journal of Haematology, 1998
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Granulocyte Colony-Stimulating Factor for Neutropenia Secondary to TiclopidineActa Haematologica, 1994
- Warfarin and azathioprine: A drug interaction does existThe American Journal of Medicine, 1993
- The antiphospholipid syndrome: ten years onThe Lancet, 1993
- A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk PatientsNew England Journal of Medicine, 1989